Taiwan study links substage, CHOP response to lymphoma survival
Bottom line
Dogs with multicentric B-cell lymphoma in Taiwan had shorter overall survival when they presented with clinical signs at diagnosis and when they failed to achieve an objective response to CHOP chemotherapy, according to a new retrospective Frontiers in Veterinary Science study. Investigators at National Taiwan University reviewed 441 canine lymphoma cases and, for survival analysis, included dogs that completed at least one full CHOP cycle. Median overall survival was 140 days for dogs in clinical substage b versus 186 days for substage a, and Cox modeling linked both clinical signs and lack of response to higher mortality risk. The authors said the study is the first to describe the epidemiology and immunophenotypes of canine multicentric B-cell lymphoma in Taiwan. (frontiersin.org)
Why it matters: For veterinary teams, the findings reinforce two practical points that already shape lymphoma care: substage still matters, and early treatment response remains one of the clearest prognostic signals in B-cell disease. Broader lymphoma literature supports CHOP-based therapy as the standard first-line approach for canine peripheral nodal B-cell lymphoma, while also showing that outcomes can vary meaningfully by phenotype, protocol course, and response depth. That makes careful staging, immunophenotyping, and early response assessment especially important when counseling pet parents about prognosis and treatment expectations. (frontiersin.org)
What to watch: Further work from Taiwan and other centers may clarify whether additional markers, including molecular or treatment-course variables, can sharpen prognosis beyond substage and initial CHOP response. (frontiersin.org)
Key facts
- Study type
- Retrospective study
- Location
- Taiwan
- Institution
- National Taiwan University
- Sample size
- 441 dogs with lymphoma
- Population
- Dogs with multicentric B-cell lymphoma
- Treatment analyzed
- CHOP chemotherapy
- Median overall survival
- 140 days for clinical substage b, 186 days for substage a
- Main finding
- Clinical signs at diagnosis and failure to achieve an objective response to CHOP were linked to higher mortality risk
- Additional finding
- No statistically significant survival difference was found for higher serum calcium or stage IV to V disease
A new retrospective study from Taiwan adds regional data to a familiar question in canine oncology: which clinical variables best track survival in dogs with multicentric B-cell lymphoma. In the Frontiers in Veterinary Science paper, researchers at National Taiwan University found that dogs with clinical signs at diagnosis and dogs that did not achieve an objective response to CHOP chemotherapy had significantly worse overall survival. (frontiersin.org)
The study helps fill a gap because, while multicentric lymphoma is one of the most common canine hematopoietic malignancies, published characterization of multicentric B-cell lymphoma in Taiwan has been limited. The authors reviewed medical records from 441 dogs with lymphoma, selecting cases with enlarged peripheral lymph nodes and large neoplastic cells on cytology or histopathology. Immunophenotyping was done mainly by flow cytometry, with PCR for antigen receptor rearrangement used in a smaller subset. (frontiersin.org)
For the overall survival analysis, the team included dogs that completed at least one full cycle of CHOP. Dogs in clinical substage b had a median overall survival of 140 days, compared with 186 days for dogs in substage a. Dogs that achieved a complete or partial response to CHOP had longer overall survival than dogs without an obvious response, and multivariable Cox analysis found both clinical signs at presentation and failure to achieve an objective response were significantly associated with increased mortality. By contrast, the study did not find statistically significant survival differences tied to higher serum calcium or more advanced stage IV to V disease. (frontiersin.org)
Those findings land in the context of a broader literature base that still treats CHOP as the benchmark first-line regimen for canine B-cell lymphoma. A large European multicenter study published in the Journal of Veterinary Internal Medicine reported similar outcomes with CHOP-19 and CHOP-25 in dogs with peripheral nodal B-cell lymphoma, underscoring that CHOP remains a standard-of-care backbone even as protocol details vary by center. That paper also noted that peripheral nodal B-cell lymphomas are the most common presentation of canine lymphoma and that most canine lymphomas present in multicentric form. (academic.oup.com)
Industry and expert commentary around canine lymphoma has increasingly emphasized that phenotyping and prognostic stratification matter in day-to-day practice. AVMA educational material highlights flow cytometry, histology with immunohistochemistry, and PARR as tools that help identify lymphoma subtype and better gauge prognosis, while oncology commentary in dvm360 has stressed that B-cell lymphoma generally carries a better outlook than T-cell disease and that CHOP-based therapy remains the standard first-line option for B-cell cases. (axon.avma.org)
Why it matters: For veterinary professionals, the Taiwan data is useful less because it overturns existing assumptions and more because it strengthens them in a sizable regional cohort. The signal around substage b supports the value of documenting systemic illness carefully at diagnosis, not just anatomic stage. The response finding is also clinically relevant for referral and primary care teams alike: early objective response may help refine prognosis discussions, support treatment planning, and identify patients who may need closer monitoring or earlier consideration of alternate strategies. At the same time, the lack of a significant association for hypercalcemia or stage IV to V disease in this cohort is a reminder that prognostic markers can perform differently across populations and study designs. (frontiersin.org)
The study also fits into a larger push toward more individualized lymphoma care. Recent research has explored whether methylation markers, immune profiling, and protocol design can sharpen prognostication or guide therapy selection in canine B-cell lymphoma, but those approaches are not yet routine across general practice. For now, the most actionable takeaways remain accessible ones: establish phenotype, document substage, start evidence-based therapy promptly when appropriate, and assess response carefully. (academic.oup.com)
What to watch: The next step is whether future Taiwan-based or multicenter studies can pair standard clinical variables with molecular markers and more granular treatment-response data to produce prognostic tools that are more precise, and more usable, at the point of care. (frontiersin.org)